Role of Phosphodiesterase 2 in Growth and Invasion of Human Malignant Melanoma Cells

Overview

Journal Cell Signal

Date 2014 Apr 8

PMID 24705027

Citations 14

Authors

Kenichi Hiramoto

Taku Murata

Kasumi Shimizu

Hiroshi Morita

Madoka Inui

Vincent C Manganiello

Toshiro Tagawa

Naoya Arai

Affiliations

Soon will be listed here.

Abstract

Cyclic nucleotide phosphodiesterases (PDEs) regulate the intracellular concentrations and effects of adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP). The role of PDEs in malignant tumor cells is still uncertain. The role of PDEs, especially PDE2, in human malignant melanoma PMP cell line was examined in this study. In PMP cells, 8-bromo-cAMP, a cAMP analog, inhibited cell growth and invasion. However, 8-bromo-cGMP, a cGMP analog, had little or no effect. PDE2 and PDE4, but not PDE3, were expressed in PMP cells. Growth and invasion of PMP cells were inhibited by erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), a specific PDE2 inhibitor, but not by rolipram, a specific PDE4 inhibitor. Moreover, cell growth and invasion were inhibited by transfection of small interfering RNAs (siRNAs) specific for PDE2A and a catalytically-dead mutant of PDE2A. After treating cells with EHNA or rolipram, intracellular cAMP concentrations were increased. Growth and invasion were stimulated by PKA14-22, a PKA inhibitor, and inhibited by N(6)-benzoyl-c AMP, a PKA specific cAMP analog, whereas 8-(4-chlorophenylthio)-2'-O-methyl-cAMP, an Epac specific cAMP analog, did not. Invasion, but not growth, was stimulated by A-kinase anchor protein (AKAP) St-Ht31 inhibitory peptide. Based on these results, PDE2 appears to play an important role in growth and invasion of the human malignant melanoma PMP cell line. Selectively suppressing PDE2 might possibly inhibit growth and invasion of other malignant tumor cell lines.

Citing Articles

Bioengineered 3D microvessels and complementary animal models reveal mechanisms of Trypanosoma congolense sequestration.

Porqueddu T, Zorrinho-Almeida M, De Niz M, Casas-Sanchez A, Introini V, Sanz Sender S Commun Biol. 2025; 8(1):321.

PMID: 40011598 PMC: 11865532. DOI: 10.1038/s42003-025-07739-z.

Migration speed of captured breast cancer subpopulations correlates with metastatic fitness.

Desjardins-Lecavalier N, Annis M, Nowakowski A, Kiepas A, Binan L, Roy J J Cell Sci. 2023; 136(13).

PMID: 37313743 PMC: 10657211. DOI: 10.1242/jcs.260835.

Low Expression of Phosphodiesterase 2 (PDE2A) Promotes the Progression by Regulating Mitochondrial Morphology and ATP Content and Predicts Poor Prognosis in Hepatocellular Carcinoma.

Chen L, Zhou J, Zhao Z, Zhu Y, Xing J, An J Cells. 2023; 12(1).

PMID: 36611861 PMC: 9818237. DOI: 10.3390/cells12010068.

Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules.

Bondarev A, Attwood M, Jonsson J, Chubarev V, Tarasov V, Liu W Front Pharmacol. 2022; 13:1057083.

PMID: 36506513 PMC: 9731127. DOI: 10.3389/fphar.2022.1057083.

cAMP-specific phosphodiesterase 8A and 8B isoforms are differentially expressed in human testis and Leydig cell tumor.

Campolo F, Capponi C, Tarsitano M, Tenuta M, Pozza C, Gianfrilli D Front Endocrinol (Lausanne). 2022; 13:1010924.

PMID: 36277728 PMC: 9585345. DOI: 10.3389/fendo.2022.1010924.

References

Janik P, Assaf A, Bertram J . Inhibition of growth of primary and metastatic Lewis lung carcinoma cells by the phosphodiesterase inhibitor isobutylmethylxanthine. Cancer Res. 1980; 40(6):1950-4. View

Dumont J, Jauniaux J, Roger P . The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci. 1989; 14(2):67-71. DOI: 10.1016/0968-0004(89)90046-7. View

Shimizu K, Murata T, Okumura K, Manganiello V, Tagawa T . Expression and role of phosphodiesterase 3 in human squamous cell carcinoma KB cells. Anticancer Drugs. 2002; 13(8):875-80. DOI: 10.1097/00001813-200209000-00014. View

Tanaka K, Iwamoto Y, Ito Y, Ishibashi T, Nakabeppu Y, Sekiguchi M . Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res. 1995; 55(13):2927-35. View

Manganiello V, Degerman E . Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb Haemost. 1999; 82(2):407-11. View

Fontana J, Miksis G, Miranda D, Durham J . Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds. J Natl Cancer Inst. 1987; 78(6):1107-12. View

de Vos H, Verschueren H, Convents A, De Baetselier P, Vauquelin G . Cyclic AMP content and invasive capacity of metastatic variants of the BW-5147 murine T-cell lymphoma. Life Sci. 1990; 46(7):497-505. DOI: 10.1016/0024-3205(90)90005-c. View

Thompson W, Piazza G, Li H, Liu L, Fetter J, Zhu B . Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000; 60(13):3338-42. View

Murata K, Sudo T, Kameyama M, Fukuoka H, Muka M, Doki Y . Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility. Clin Exp Metastasis. 2001; 18(7):599-604. DOI: 10.1023/a:1011926116777. View

10.

Chen T, Hinton D, Zidovetzki R, Hofman F . Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest. 1998; 78(2):165-74. View

11.

Murashima S, Tanaka T, Hockman S, Manganiello V . Characterization of particulate cyclic nucleotide phosphodiesterases from bovine brain: purification of a distinct cGMP-stimulated isoenzyme. Biochemistry. 1990; 29(22):5285-92. DOI: 10.1021/bi00474a010. View

12.

Kenan Y, Murata T, Shakur Y, Degerman E, Manganiello V . Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. J Biol Chem. 2000; 275(16):12331-8. DOI: 10.1074/jbc.275.16.12331. View

13.

Slungaard A, Confer D, Schubach W . Rapid transcriptional down-regulation of c-myc expression during cyclic adenosine monophosphate-promoted differentiation of leukemic cells. J Clin Invest. 1987; 79(5):1542-7. PMC: 424433. DOI: 10.1172/JCI112987. View

14.

Bender A, Beavo J . Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006; 58(3):488-520. DOI: 10.1124/pr.58.3.5. View

15.

Lichtner R, Nicolson G . The pyrimido-pyrimidine derivatives RA 233 and RX-RA 85 affect growth and cytoskeletal organization of rat mammary adenocarcinoma cells. Eur J Cancer Clin Oncol. 1987; 23(9):1269-75. DOI: 10.1016/0277-5379(87)90107-6. View

16.

Drees M, Zimmermann R, Eisenbrand G . 3',5'-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res. 1993; 53(13):3058-61. View

17.

Murata T, Taira M, Manganiello V . Differential expression of cGMP-inhibited cyclic nucleotide phosphodiesterases in human hepatoma cell lines. FEBS Lett. 1996; 390(1):29-33. DOI: 10.1016/0014-5793(96)00410-3. View

18.

Stangherlin A, Gesellchen F, Zoccarato A, Terrin A, Fields L, Berrera M . cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res. 2011; 108(8):929-39. PMC: 3083836. DOI: 10.1161/CIRCRESAHA.110.230698. View

19.

Beavo J, Hardman J, SUTHERLAND E . Hydrolysis of cyclic guanosine and adenosine 3',5'-monophosphates by rat and bovine tissues. J Biol Chem. 1970; 245(21):5649-55. View

20.

Yamamoto T, Manganiello V, Vaughan M . Purification and characterization of cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from calf liver. Effects of divalent cations on activity. J Biol Chem. 1983; 258(20):12526-33. View